miR-155 Expression in the Serum of Patients with Ductal Carcinoma in Situ (DCIS) of the Breast and Patients with Invasive Ductal Carcinoma (IDC) of the Breast

Abstract

Background: Breast cancer (BC) is an illness affecting millions of women across the world. The transition from ductal carcinoma in situ to invasive ductal breast cancer is a crucial event in the progress that is still not well understood. microRNAs (miRNAs) have recently been documented to play an important role in cancer development. miRNAs have been discovered to control this critical transition. The miR-155 plays an essential role in the pathogenesis of breast cancer. miR-155 has been implicated in developing breast cancer. Objectives: This study aimed to investigate the expression of miR-155 in the serum of patients with breast cancer, according to clinical characteristics (DCIS and IDC) of breast cancer. Methods: 60 patients referring to hospitals in Ahvaz during 2012 and 2015 were divided into 2 groups according to clinical characteristics (DCIS and IDC). miRNA was extracted, and complementary DNA (cDNA) was synthesized in line with the guidelines of the Kit manufacturer. A real-time PCR method was performed as the expression assay. Results: The mean expression level of miR-155 in DCIS group was 6.45 ± 0.545. In addition, the mean expression level of miR-155 in serum of DCI group was 40.42 ± 0.742; the difference was statistically significant (P < 0.0001). Conclusions: Based on the results of this study, the serum level of miR-155 evidenced a statistically significant difference in invasive breast cancer (IDC) patients. The study results showed that checking the serum level of miR-155 expression in patients with invasive breast cancer (IDC) might be helpful.